Prevalence and clinical features of HIV and malaria co-infection in hospitalized adults in Beira, Mozambique

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Saracino, Annalisa ^a,b   Nacarapa, Edy A ^c   Da Costa Massinga, Ézio A ^c   Martinelli, Domenico ^b   Scacchetti, Marco ^a   De Oliveira, Carlos ^d   Antonich, Anita ^a   Galloni, Donata ^a   Ferro, Josefo J ^c   MacOme, César A ^d  

^a Africa CUAMM Mozambique   (Mozambique)

^b UNIVERSITY OF FOGGIA   (Italy)

^c Ilha de Moc mbique   (Mozambique)

^d Central Hospital of Beira Mozambique   (Mozambique)

Author keywords

Antiretrovirals; Cotrimoxazole; HIV; Malaria; Mozambique

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; HEMOGLOBIN; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE;

ADULT; ARTICLE; BLOOD SMEAR; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL STUDY; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION PREVENTION; INFECTION RISK; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALARIA; MALE; MIXED INFECTION; MOZAMBIQUE; OPPORTUNISTIC INFECTION; PARASITE PREVALENCE; SENSITIVITY AND SPECIFICITY;

ADULT; ANTI-HIV AGENTS; ANTIMALARIALS; COINFECTION; COMORBIDITY; FEMALE; HIV INFECTIONS; HOSPITALS; HUMANS; MALARIA; MALE; MIDDLE AGED; MOZAMBIQUE; PREVALENCE; YOUNG ADULT;

EID: 84864133962     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-241     Document Type: Article

References (24)

1. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Centers for Disease Control and Prevention, mMWR 2009 58 N RR4 94 98
2. Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. Rana FS, Hawken MP, Mwachari C, Bhatt SM, Abdullah F, Ng'ang'a LW, Power C, Githui WA, Porter JD, Lucas SB, J Acquir Immune Defic Syndr 2000 24 23 29 10877491 (Pubitemid 30447802)
3. Review of human immuno deficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Holmes CB, Losina E, Walensky RP, Yazdanpanah Y, Freedberg KA, Clin Infect Dis 2003 36 652 62 10.1086/367655 12594648 (Pubitemid 36259573)
4. Consequences of HIV infection on malaria and therapeutic implications: a systematic review. Flateau C, Le Loup G, Pialoux G, Lancet Infect Dis 2011 11 541 56 10.1016/S1473-3099(11)70031-7 21700241
5. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Mermin J, Ekwaru JP, Liechty CA, Were W, Downing R, Ransom R, Weidle P, Lule J, Coutinho A, Solberg P, Lancet 2006 367 1256 61 10.1016/S0140-6736(06)68541-3 16631881
6. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. Thera MA, Sehdev PS, Coulibaly D, Traore K, Garba MN, Cissoko Y, Kone A, Guindo A, Dicko A, Beavogui AH, Djimde AA, Lyke KE, Diallo DA, Doumbo OK, Plowe CV, J Infect Dis 2005 192 823 29
7. HIV Epidemiological Surveillance Round, 2007.maputo, National Directorate of Medical Care, National STD/HIV/AIDS Control Program Ministry of Health, Mozambique 2008
8. UNAIDSCFS-AFRMOZ, EPIChart 2011 last-access-11-20-2011-10.00.16-AM, http://aidsinfo.unaids.org
9. Worldmalaria Report 2010 http://www.who.int/malaria/world-malaria-report- 2010/worldmalariareport2010.pdf
10. Falciparum malaria and HIV-1 in hospitalized adults in maputo,mozambique: does HIV-infection obscure the malaria diagnosis? Berg A, Patel S, Langeland N, Blomberg B, Malar J 2008 7 252 10.1186/1475-2875-7-252 19077302
11. Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of wide spread antifolate resistance. Gasasira AF, Kamya MR, Ochong EO, Vora N, Achan J, Charlebois E, Ruel T, Kateera F, Meya DN, Havlir D, Rosenthal PJ, Dorsey G, Malar J 2010 9 177 10.1186/1475-2875-9-177 20573194
12. Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in malawi. Kapito-Tembo A, Meshnick SR, van Hensbroek MB, Phiri K, Fitzgerald M, Mwapasa V, J Infect Dis 2011 203 464 472 10.1093/infdis/jiq072 21216867
13. Daily co-trimoxazole prophylaxis in severely immuno suppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Walker AS, Forda D, Gilksb CF, Munderic P, Ssalid F, Reide A, Katabiraf E, Grosskurthc H, Mugyenyid P, Hakime J, Darbyshirea JH, Gibba DM, Babikera AG, Lancet 2010 37 1278 1286
14. Antimalarial activity of human immuno deficiency virus type 1 protease inhibitors. Parikh S, Gut J, Istvan E, Goldberg DE, Havlir DV, Rosenthal PJ, Antimicrob Agents Chemother 2005 49 2983 2985 10.1128/AAC.49.7.2983-2985.2005 15980379 (Pubitemid 40917621)
15. Antiretrovirals as anti malarial agents. Skinner-Adams TS, McARThy JS, Gardiner DL, Hilton PM, Andrews KT, J Infect Dis 2004 190 1998 2000 10.1086/425584 15529265 (Pubitemid 39564706)
16. Stronger activity of human immuno deficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P falciparum. Lek-Uthai U, Suwanarusk R, Ruengweerayut R, Skinner-Adams TS, Nosten F, Gardiner DL, Boonma P, Piera KA, Andrews KT, Machunter B, McARThy JS, Anstey NM, Price RN, Russell B, Antimicrob Agents Chemother 2008 52 2435 2441 10.1128/AAC.00169-08 18443130 (Pubitemid 351915673)
17. Antimalarial activity of sera from subjects taking HIV protease inhibitors. Redmond AM, Skinner-Adams T, Andrews KT, Gardiner DL, Ray J, Kelly M, McARThy JS, AIDS 2007 21 763 765 10.1097/QAD.0b013e328031f41a 17413699 (Pubitemid 46568635)
18. HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites. Hobbs CV, Voza T, Coppi A, Kirmse B, Marsh K, Borkowsky W, Sinnis P, J Infect Dis 2009 199 134 141 10.1086/594369 19032102
19. Potencies of human immuno deficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murinemalaria. Andrews KT, Fairlie DP, Madala PK, Ray J, Wyatt DM, Hilton PM, Melville LA, Beattie L, Gardiner DL, Reid RC, Stoermer MJ, Skinner-Adams T, Berry C, McArthy JS, Antimicrob Agents Chemother 2006 50 639 648 10.1128/AAC.50.2.639-648.2006 16436721 (Pubitemid 43190977)
20. Low prevalence of Plasmodium falciparum antigenaemia among asymptomatic HAART treated adults in an urban cohort in Uganda. Nakanjako D, Kiragga AN, Castelnuovo B, Kyabayinze DJ, Kamya MR, Malar J 2011 10 66 10.1186/1475-2875-10- 66 21426579
21. Four-year treatment outcomes of adult patients enrolled in mozambiques rapidly expanding antiretroviral therapy program. Auld AF, Mbofana F, Shiraishi RW, Sanchez M, Alfredo C, Nelson LJ, Ellerbrock T, PLoS ONE 2011 6 18453 10.1371/journal.pone.0018453
22. Auto immune thrombocytopenic purpura in homosexual men. AUmorris L, Distenfeld A, Amorosi E, Karpatkin S, Ann Internmed 1982 96 6 Pt 1 714
23. Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women. Berhane K, Karim R, Cohen M, Masri-Lavine L, Young M, Anastos K, Augenbraun M, Watts DH, Levine A, JAIDS 2004 37 1245 1252 10.1097/01.qai.0000134759.01684.27 15385731 (Pubitemid 39281505)
24. Impact of HIV-1 infection on the hematological recovery after clinical malaria. Van Geertruyden JP, Mulenga M, Chalwe V, Michael N, Moerman F, Mukwamataba D, Colebunders R, D'Alessandro U, J Acquir Immune Defic Syndr 2009 50 200 205 10.1097/QAI.0b013e3181900159 19131887